ACRV · Acrivon Therapeutics, Inc.
Market Cap
$89.13M
Shares
42.85M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 10-Q | 2026-08-12 | 2026-06-30 | |
| 8-K | 2026-08-12 | — | |
| 8-K | 2026-06-17 | — | |
| 8-K | 2026-05-13 | — | |
| 10-Q | 2026-05-13 | 2026-03-31 | |
| DEF 14A | 2026-04-30 | 2026-06-17 | |
| 10-K | 2026-03-19 | 2025-12-31 | |
| 8-K | 2026-03-19 | — | |
| 8-K | 2026-03-02 | 2026-02-25 | |
| 8-K | 2026-02-27 | — | |
| 8-K | 2026-01-08 | — | |
| 8-K | 2026-01-08 | — | |
| 10-Q | 2025-11-13 | 2025-09-30 | |
| 8-K | 2025-11-13 | — | |
| 8-K | 2025-09-05 | — | |
| 10-Q | 2025-08-13 | 2025-06-30 | |
| 8-K | 2025-08-13 | — | |
| 8-K | 2025-06-13 | — | |
| 8-K | 2025-05-14 | — | |
| 10-Q | 2025-05-14 | 2025-03-31 | |
| DEF 14A | 2025-04-25 | 2025-06-13 | |
| 8-K | 2025-04-07 | — | |
| 10-K | 2025-03-27 | 2024-12-31 | |
| 8-K | 2025-03-27 | — | |
| 8-K | 2025-03-25 | — | |
| 8-K | 2025-03-14 | 2025-03-11 | |
| 10-Q | 2024-11-13 | 2024-09-30 | |
| 8-K | 2024-11-13 | — | |
| 8-K | 2024-10-11 | — | |
| 8-K | 2024-09-16 | 2024-09-14 | |
| 8-K | 2024-08-13 | — | |
| 10-Q | 2024-08-13 | 2024-06-30 | |
| 8-K | 2024-06-21 | 2024-06-20 | |
| 10-Q | 2024-05-14 | 2024-03-31 | |
| 8-K | 2024-05-14 | — | |
| DEF 14A | 2024-04-26 | 2024-06-20 | |
| 8-K | 2024-04-24 | — | |
| 8-K | 2024-04-09 | 2024-04-08 | |
| 8-K | 2024-03-28 | — | |
| 10-K | 2024-03-28 | 2023-12-31 | |
| 8-K | 2024-03-04 | — | |
| 8-K | 2024-02-08 | 2024-02-07 | |
| 8-K | 2024-01-08 | — | |
| 8-K | 2023-12-08 | 2023-12-04 | |
| 10-Q | 2023-11-09 | 2023-09-30 | |
| 8-K | 2023-11-09 | — | |
| 8-K | 2023-09-05 | — | |
| 8-K | 2023-08-11 | — | |
| 10-Q | 2023-08-11 | 2023-06-30 | |
| 8-K | 2023-06-22 | — |
Showing 1–50 of 63 filings
Key facts
CIK
1781174
CUSIP
004890109
13F (30d)
44 filings
44 filers
Visit website
Investor relations